Merck, Nvidia, Microsoft, Dawn Health Build Rare Tumor Model

The pairing is the story: a pharma incumbent bringing the clinical and biological context, two hyperscalers supplying compute and cloud infrastructure, and a digital-health specialist handling deployment. That division of labor is becoming the template for AI in drug R&D, and rare tumors are a deliberate test case — small patient populations mean less data, so model design matters more than scale. The absence of financial terms or a timeline leaves the commitment level unclear, and whether this produces a reusable platform or a single-disease pilot is the open question worth watching.